Form 4: Halozyme Legal Officer's Routine Stock Transactions

Halozyme Therapeutics' SVP, Chief Legal Officer, Mark Howard Snyder, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Summary

• Mark Howard Snyder, Senior Vice President and Chief Legal Officer of Halozyme Therapeutics, Inc. (HALO), reported transactions involving the company's common stock.
• On January 3, 2026, Mr. Snyder acquired 7,611 shares of common stock through the vesting and settlement of restricted stock units (RSUs) at a price of $0.00 per share.
• Concurrently, Mr. Snyder disposed of 4,243 shares of common stock to satisfy tax withholding obligations related to the RSU vesting, with these shares valued at $70.31 each.
• Following these transactions, Mr. Snyder's direct beneficial ownership of Halozyme Therapeutics common stock stands at 34,181 shares.
• The derivative securities (Restricted Stock Units) held by Mr. Snyder decreased by 7,611 units, resulting in zero derivative securities beneficially owned after the conversion to common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the vesting of restricted stock units and subsequent tax-related share disposition, which is a standard compensation event and does not indicate a positive or negative operational development.

Positives

• The vesting of 7,611 restricted stock units indicates a component of executive compensation being realized, aligning management's interests with shareholders.

Negatives

• The disposition of 4,243 shares to cover tax withholding obligations, while a standard practice, reduces the executive's direct shareholding.

Future Outlook

This filing is a report of past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction for an executive in the biotechnology industry, which is a common occurrence as part of executive compensation plans. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The transaction is a routine compensation event and does not directly impact the company's operational performance or strategic direction. It reflects the realization of executive compensation.
• Employees: The vesting of RSUs is a standard component of executive compensation, which can be a positive signal for employee incentive programs.

Key Dates

Recommendation

The Form 4 filing details a routine insider transaction where an executive received shares from RSU vesting and subsequently sold a portion to cover tax obligations. This is a standard compensation event and does not provide new information that would alter the fundamental investment thesis for Halozyme Therapeutics, thus a 'hold' recommendation is appropriate.

Keywords

Halozyme Therapeutics, HALO, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Disposition, Tax Withholding